James Black

Vertex Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

4h-index827citations5works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(1), Acute Myeloid Leukemia Research(1), HIV/AIDS drug development and treatment(1), PI3K/AKT/mTOR signaling in cancer(1), Cytomegalovirus and herpesvirus research(1)

Publications5 total

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry·2015· 87 cited
Pim-1 Ligand-bound Structures Reveal the Mechanism of Serine/Threonine Kinase Inhibition by LY294002
Journal of Biological Chemistry·2005· 187 citedOpen Access
The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain
Molecular Cell·2004· 495 citedOpen Access
Biochemical Analysis of the Modular Enzyme Inosine 5′-Monophosphate Dehydrogenase
Protein Expression and Purification·1999· 58 cited
Free Speech & The Internet: The Inevitable Move Toward Government Regulation
Richmond journal of law & technology·1997

Frequent Co-authors

Lora Swenson(3), Kumkum Saxena(3), Olga Futer(2), Christopher L. Brummel(2), Scott A. Raybuck(2), James Griffith(1), Carlos H. Faerman(1), Michael Wynn(1), Fan Lu(1), Judith A. Lippke(1), Marc Jacobs(1), Brian Hare(1), Mark Fleming(1), Luc J. Farmer(1), Mark W. Ledeboer(1), Thomas Hoock(1), Michael Arnost(1), Randy S. Bethiel(1), Youssef L. Bennani(1), Ananthsrinivas Chakilam(1)